AAIPharma Acquires Celsis Unit

AAIPharma Services Corp. has acquired Celsis Analytical Services, a division of Celsis International Ltd. that performs material testing services for the pharmaceutical, biotechnology and manufacturing sectors. Financial terms were not disclosed.

“The addition of Celsis Analytical Services will enable AAIPharma to expand its market presence in two key regions. Our combined company will bring a differentiated offering to the contract services market with an integrated development and material testing service model,” said Patrick Walsh, chief executive officer of AAIPharma. “We are excited to integrate Celsis labs’ business with AAIPharma, creating one of the largest and most experienced materials testing businesses in the U.S.”

Celsis Analytical Services provides outsourced cGMP lab services at its lab operations in Edison, NJ and St. Louis, MO. Both testing centers comprise 65,000 sq. ft., adding to AAIPharma’s existing 300,000 sq. ft. of facilities. The combined entity offers a comprehensive portfolio of methods validation and testing services for biotechnology, pharmaceutical and consumer products manufacturers, raw materials suppliers and manufacturers of agricultural and veterinary medicine products.

“Celsis Analytical Services and AAIPharma have very complementary client bases and can provide a comprehensive range of testing services to the growing pharmaceutical and biotechnology outsourcing market,” said Jay LeCoque, chief executive officer of Celsis International Ltd. “This acquisition will enable each of the locations to participate more fully in the growth of the contract services market and to enjoy the synergies offered by the larger combined company.”